Literature DB >> 24101856

Efficacy of yoga in treatment of migraine.

Arvind Kankane1.   

Abstract

Entities:  

Year:  2013        PMID: 24101856      PMCID: PMC3788320          DOI: 10.4103/0972-2327.116961

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
Sir, I read the review article “The therapeutic value of yoga in neurological disease”[1] with great interest. Yoga, coupling physical exercise with breathing and relaxation, is a popular alternative form of mind body therapy. Yoga has long been used to reduce physical symptoms of chronic pain. It also helps an individual deal with emotional aspect of chronic pain by reducing anxiety and depression. I want to highlight efficacy of yoga in treatment of migraine headache. John et al,[2] studied the effectiveness of yoga therapy in treatment of migraine without aura. In a randomized control trial, 72 patients with migraine without aura were randomly assigned to yoga therapy or self-care group for three months. Primary outcomes were headache frequency, severity, and pain component. Secondary outcomes were anxiety, depression, and medication score. The subjects in yoga group had statistically significant improvement in headache intensity, frequency, sensory pain rating index, affective pain rating index, total pain rating index, anxiety and depression score, and symptomatic medication use. Although this study provides preliminary evidences regarding efficacy of yoga in patients with migraine, yet it opens a door and provides directions for further research in this field.
  2 in total

1.  Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial.

Authors:  P J John; Neha Sharma; Chandra M Sharma; Arvind Kankane
Journal:  Headache       Date:  2007-05       Impact factor: 5.887

2.  The therapeutic value of yoga in neurological disorders.

Authors:  Shri K Mishra; Parampreet Singh; Steven J Bunch; Ray Zhang
Journal:  Ann Indian Acad Neurol       Date:  2012-10       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.